Liver, cardiovascular and metabolic factors

as predictors of all-cause mortality

in a rural Ugandan Cohort

Cori Campbell[1,2]*, Joseph Mugisha[3]*, Beatrice Kimono[3], Elizabeth Waddilove[4],

Ronald Makanga[3], Tingyan Wang[1,2], Florence Nambaziira Muzaale[3],

Philippa C Matthews[4-7]†, Robert Newton[8]†#

1. NIHR Oxford Biomedical Research Centre, Oxford, UK

2. Nuffield Department of Medicine, University of Oxford, Oxford, UK

3. Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.

4. The Francis Crick Institute, London, UK

5. NIHR Health Informatics Collaborative, Oxford University Hospitals NHS Foundation Trust,

Oxford, UK

6. Division of Infection and Immunity, University College London, London, UK

7. Department of Infectious Diseases, University College London Hospital, London, UK

8. Department of Health Sciences, University of York, York, United Kingdom.

* Joint first authors

† joint senior authors

Corresponding author: Robert.newton@york.ac.uk

27   **Keywords:** Liver function tests, hypertension, diabetes, MASLD, mortality, HIV, HBV,

28   Uganda, epidemiology

Abstract

Markers of liver and metabolic disease have not been well described for African populations but could be crucial to inform population health interventions that reduce morbidity and mortality. We studied a population in rural Uganda to describe the baseline and longitudinal distributions of liver function tests, and to investigate how liver, metabolic and cardiovascular parameters are associated with all-cause mortality. Demographic and laboratory data were collected through the General Population Cohort (GPC) in South-Western Uganda. We summarised cohort characteristics at baseline using descriptive statistics, and used univariable and multivariable Cox proportional hazards models to investigate factors associated with hazards of death. Our dataset includes 7896 individuals, of whom 56.2% were female and 72.5% were aged under 45 years. Prevalence of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) was 2.7% and 7.4%, respectively. Death was associated with older age (p<0.0001), male sex (aHR 1.56, 95% CI 1.3 to 1.86) and HIV positivity (aHR 1.67, 95% CI 1.25 to 2.22). Excess mortality was associated with alcohol intake, based on increasing hazard of death associated with increase in AST:ALT ratio and increased serum gamma glutamyl transferase. A 10mmHg increase in systolic blood pressure was associated with 7% increased hazards of death (aHR 1.07, 95% CI 1.03 to 1.11), and one unit increases in serum HbA1c were associated with 25% increased hazards of death (aHR 1.25, 95% CI 1.13 to 1.38). Under sensitivity analysis restricted to a subset of participants with longitudinal follow-up data (n=871), HBV infection was associated with death (aHR 5.38, 95% CI 2.01-14.42). Simple interventions to tackle hypertension, diabetes, alcohol intake, and to diagnose and treat HIV and HBV infection would have a significant impact on mortality in this setting.

Introduction

Health surveillance data are urgently needed to better represent populations in the WHO Africa region in order to inform clinical and public health interventions. In this study, we focus on liver health, alongside cardiovascular and metabolic measurements and biomarkers, to provide a description of a rural East African setting which can support the shaping of community health programmes.

Hepatic enzymes and biomarkers can be measured in serum to assess liver health (1); these markers are often collectively referred to as 'liver function tests' (LFTs), and include alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl-transferase (GGT), bilirubin (BR) and albumin (Alb). LFT derangement is not only a hallmark of liver disease, trauma or hypoxia, but can also arise in association with extrahepatic or multi-system pathology, including cardiovascular disease and metabolic disease. Liver disease causes a huge burden of morbidity and mortality worldwide, with metabolic liver disease, alcohol and viral hepatitis as leading causes (1), but the epidemiology is changing over time and by region. There is an increasing recognition of the high burden of metabolic liver disease, with recently updated terminology that defines metabolic dysfunction-associated steatotic liver disease (MASLD) (2,3). LFT derangement has been associated with systemic outcomes including all-cause mortality in a variety of contexts (4–10), including increasing recognition that MASLD is a risk factor for mortality (11).

While LFTs may be of utility in characterising liver disease and in predicting outcomes, the extent to which different markers are relevant in different population settings is not clearly established (12). Commonly used thresholds for LFT derangement (13,14) have been developed in discrete and homogenous populations (more typically in the global North and in high income settings) and therefore may not be sensitive or specific in other settings (15). Furthermore, LFT measurement is most commonly undertaken in hospital/secondary care

settings, and therefore many studies are not representative of the wider population.

Hypertension, high LDL-cholesterol and elevated HBa1C are well-recognised risk factors for

cardiovascular mortality, and these parameters need scrutiny in rural African populations in

whom monitoring and intervention are often neglected (16).

We reviewed data from a rural East African setting, collected through the MRC General

Population Cohort (GPC), a prospective longitudinal population cohort located in the South

West of Uganda (17). Our specific objectives were to i) describe the baseline and

longitudinal distributions of LFTs in the GPC, and ii) investigate how LFTs, metabolic and

cardiovascular parameters in this setting associated with all-cause mortality, and can

therefore be used to help track disease patterns over time and inform population health

interventions and resource allocation.

Methods

Study design and participant sample

The General Population Cohort (GPC), located in the Ugandan Kyamulibwa sub-county of

the Kalungu district, is a prospective population cohort under longitudinal follow up (17). The

framework was originally established in 1989 to monitor HIV incidence and prevalence in the

region. An annual census is undertaken to identify participants for the medical survey. In

most waves, all individuals aged ≥13 years planning to reside ≥3 months in a household

located within the study region are eligible for inclusion, with age restrictions relaxed to

include younger participants in certain survey rounds. GPC participants have been

prospectively followed-up to detect relevant endpoints, and participant data from the survey

are linked to data collected at the Medical Research Council (MRC) / Uganda Virus

Research Institute (UVRI) clinic via unique individual identifiers. The clinic provides care to

participants with acute medical conditions, along with some chronic morbidities including HIV

infection and diabetes mellitus.

Data collected in each survey round include demographic factors, biophysical

measurements (height, weight, blood pressure and body mass index (BMI, kg/m^2)). BMI

between 18.5 and 24.9 kg/m^2 was classified as healthy weight, with <18.5 being

underweight, and >24.9 overweight. Laboratory analysis of blood samples has been

undertaken at intermittent timepoints, subject to availability of funding (not all parameters are

measured at every survey round due to cost implications).

For this study, we used LFTs data from survey round 22 (years 2011-12) and LFT resurvey

at years 2014-15) (**Figure 1**), which we defined as 'baseline' and 're-survey' timepoints

respectively. We also report round 22 data for metabolic biomarkers (including hemoglobin

A1c (HbA1c), high density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides).

Participants were also screened for Human Immunodeficiency Virus (HIV) and Hepatitis B

Virus (HBV) infection in survey round 22. Children aged 3-12 years were included in round

22, however round 24 was restricted to those aged ≥ 13 years. Follow-up data for mortality

analyses were collected up to years 2022-23.

Socio-demographic data were gathered by interviewers who administered questionnaires to

a household head or any adult representative. TheWHO STEPwise Approach to

Surveillance

questionnaire was used to collect cardiovascular risk data from individuals (18). Biophysical

measurements (blood pressure, weight, height, waist and hip circumferences) and

biochemical analysis (HbA1c, TC, HDL-C, and triglycerides (TG)) were performed using

standardised procedures described elsewhere (19,20). Blood pressure was measured on

the right arm using appropriate cuff sizes (regular arm cuff size if arm circumference was 24-

32cm,

large arm cuff if arm circumference was 33-41cm, thigh cuff if over 41cm and if under 24cm

paediatric cuff size was used) in a sitting position, three times within resting intervals of 5

minutes, using a digital sphygmomanometer (the Omron M4-I). The mean of the second and third reading was taken for analysis. Body weight was measured using the Seca 761 mechanical scales and body height was measured using a portable Leicester stadiometer to the nearest 1 kg and 0.1 cm respectively, with participants wearing light clothing and no shoes.

LFTs (serum AST, ALT, ALP, GGT and BR) were measured using a Cobas Integra 400 plus machine, with Roche reagents (15). Screening for HIV testing was done using an algorithm recommended by the Uganda Ministry of Health, based on initial screening with a rapid test. If the test result was negative, the participant was considered to be HIV negative. If the test result was positive, the sample was retested with the rapid test HIV-1 or HIV-2 Stat-Pak. If both tests resulted in a positive result, the participant was diagnosed as HIV positive. If the tests gave discordant results, the sample was further evaluated with the rapid test Uni-Gold Recombinant HIV-1/2. For those samples assessed by all three tests, two positive test results were interpreted as positive, and two negative results were considered negative. HBV surface antigen (HBsAg) testing was conducted using Cobas HBsAg II (2011–08 V.10), and those who tested positive were invited for further serologic testing. HCV was tested using a combination of immunoassays followed by PCR, as previously described (O'Hara et al). Normal serum levels of liver enzymes were classified according to the American reference range (ARR, MGH Clinical Laboratories) and local reference ranges (LRR18; values are listed in online supplementary table 1).5 We excluded individuals ≤19 years from ALP analysis, since elevated ALP can be attributable to bone growth in teenagers. Data from the full blood count was used to calculate fibrosis scores (mean corpuscular volume and platelet count). This was collected starting part-way through the 2011 data collection period; the data are, therefore, population-based, although based on only a subset of the whole cohort (n=1877). Calculation of fibrosis scores and AST/ALT ratio Where data were available (n=1877), we calculated APRI, FIB-4, GPR, RPR and S-index. The formulae for calculating these scores are presented in online supplementary table 2,5 along with the sensitivity and specificity of each, based on previous studies. We used previously

established thresholds to suggest the presence of liver fibrosis, as follows: APRI>0.7,[26] FIB-

4>3.25,[27] GPR>0.32,[13] RPR>0.8252[8] and S-index> 0.3.[29] We also calculated the

AST/ALT ratio; a score >2 has been associated with alcoholic hepatitis.

Ethics and reporting

Ethics approval was provided by the Science and Ethics Committee of the Uganda Virus

Research Institute (GC/127/12/11/06), the Ugandan National Council for Science and

Technology (HS870) and the East of England-Cambridge South (formerly Cambridgeshire 4)

NHS Research Ethics Committee UK (11/H0305/5). All adults provided informed consent for

participation including collection of data and samples. Parental/guardian consent for those

less than 18 years of age were obtained following Uganda National Council of Science and

Technology (UNCST) guidelines. The research is supported by an active community

engagement programme providing health advice and information about research projects,

and addressing questions and feedback. To ensure consistency of reporting, we have

included a STROBE (STrengthening the Reporting of OBservational studies in

Epidemiology) statement (Table S1).

Follow up and outcome ascertainment

The primary outcome for this analysis was death from any cause. Death was ascertained by

from mortality registers and verbal autopsy (21). Mortality registers are updated on a

monthly basis using reports from community health workers and verbal autopsies.

We used two definitions of ALT derangement to investigate associations with all-cause

mortality.

(i)   We applied ALT thresholds set by the United Kingdom (UK) National Institute for

Health and Care Excellence (NICE) clinical guidelines (13), defined as a serum

concentration > 19 U/L in females and >30 U/L in males.

(ii)   We calculated the proportion of the population with AST:ALT ratio ≥2, which can

194   be used as a marker of alcohol-related liver disease (22–25).

Statistical analysis

We summarised cohort characteristics at baseline using descriptive statistics, summarising

continuous laboratory parameters with means and standard deviations (SDs), or medians

and interquartile ranges (IQRs), and by division using quintiles.

We used univariable and multivariable Cox proportional hazards models to investigate

factors associated with hazards of all-cause mortality. The main multivariable model was

undertaken in participants surveyed at baseline who had complete information regarding

demographic factors, biophysical measurements and markers quantified from blood samples

(including LFTs and metabolic biomarkers). Factors were included in multivariable models

according to both significance of univariable associations (where *P* ≤0.1) and/or based on

biological/clinical relevance and previous literature from both the GPC (17,21) and

investigations undertaken in differing patient populations (4–10). We calculated univariable

hazards ratios (HRs) and multivariable adjusted hazards ratios (aHRs), along with 95%

confidence intervals (95% CI), as model outputs. Statistical analyses were performed in R

(version 4.1.0).

To interrogate the association of BMI with HbA1c in this population, the association between

the two variables was visualised, and a nonlinear relationship was fit using a generalised

additive model (Fig S1).

Sensitivity analyses

We performed two sensitivity analyses. First, the multivariable Cox proportional hazards

model excluded patients who died within 3 years of baseline LFT measurement, to

investigate the influence of reverse causality bias on the findings from the main model.

Second, we analysed the subset of patients who had LFTs measured at both baseline and

resurvey (years 2014-15), to compare the robustness of main-model results against a model

accounting for longitudinal changes in LFTs.

RESULTS

Baseline characteristics

At baseline, we included data representing 7896 individuals (**Table 1**). There was a slight

female excess (4441/7896, 56.2%), and participants aged <45 years accounted for the

majority (5722/7896, 72.5%). BMI ranged between 18.5 and 24.9 kg/m^2 for the majority

(4769/7896, 64.8%), representing a healthy range. Hepatitis B virus (HBV) infection was

present in 2.7% (216/7896) and HIV in 7.4% (582/7896). Participants were followed up for a

mean 6.4 (SD 3.2) years.

Longitudinal LFT trends

LFTs were quantified at re-survey in 898 (11.4%) participants (**Table 2**). Median values of

ALT, AST and GGT had fallen compared to baseline, and thus smaller proportions of

participants had abnormal ALT values (classified according to NICE) at follow-up (28.7% vs

13.8%, P < 0.001). In contrast, median AST:ALT ratio was higher at resurvey, with an

increase in the proportion of the population with ratio >2, from 11.2% at baseline to 36.0% at

resurvey (P < 0.001).

Risk factors for all-cause mortality

The main complete-case multivariable model included 7341 participants, of whom 563

(7.7%) died throughout follow-up We identified risk factors for all-cause mortality (**Figure 2,**

S3). As expected, mean age was older (59.4 years, SD 19.5) in those who died as

compared to those who survived (31.8, SD 16.5) (*P* < 0.001). Increased hazards of death

during the period of observation were also associated with male sex (aHR 1.56, 95% CI 1.3

to 1.86) and HIV positivity (aHR 1.67, 95% CI 1.25 to 2.22).

A one unit increase in AST:ALT ratio was associated with 32% increase in death hazards

(aHR 1.17, 95% CI 1.08 to 1.26), while 10-unit increases in serum GGT were associated

with 1% increased hazards (aHR 1.01, 95% CI 1.01 to 1.01). Both of these markers are

associated with alcohol excess. Conversely, hazards were reduced with increased serum

albumin, for which a one unit increase predicted a 10% reduction in hazards of death (aHR

0.86, 95% CI 0.85 to 0.87).

On assessment of cardiovascular and metabolic factors, a 10mm Hg increase in systolic

blood pressure was associated with 7% increased hazards of death (aHR 1.07, 95% CI 1.03

to 1.11), and one unit increases in serum HbA1c were associated with 25% increased

hazards of death (aHR 1.25, 95% CI 1.13 to 1.38). Although HbA1c is associated with BMI

(S4), there was no statistically significant relationship between BMI and death. Reduced

hazards of death were observed in the second LDL quintile (aHR 0.67, 95% CI 0.5 to 0.89)

compared to the first quintile, but there were no associations for the other quintile groups.

Sensitivity analyses

The first sensitivity analysis undertaken was based on data from 5641 participants, which

excluded deaths occurring within the first three years of follow-up (S3). In general, the

associations observed in the main multivariable model remained unchanged in terms of both

direction and magnitude. However, the association of HIV positivity with increasing hazards

of death was attenuated towards the null.

The second sensitivity analysis undertaken was restricted to the smaller set of participants

with longitudinal LFT measurement (n-871), and utilised a time-updated Cox proportional

hazards model to incorporate changes in LFT serum concentrations over time (S3). Most

associations observed in the main multivariable model remained unchanged in direction.

Confidence intervals for all associations were widened due to the smaller number of

observations. AST:ALT ratio and HbA1c were no longer significantly associated with

mortality in this sensitivity analysis. However, HBV-positive status became significant, with a

hazard ratio for mortality of 5.38 (95% CI 2.01-14.42).

DISCUSSION

Clinical and public health relevance of findings

Liver related morbidity and mortality are poorly studied in African populations, despite being

a significant public health problem. Measurement of LFTs and metabolic biomarkers across

a population has provided insights into the extent of abnormalities, and allowed us to

determine an association with mortality.

Evidence that broad markers of liver health can be used to predict outcomes may help to

inform specific understanding of drivers of morbidity and mortality. For example, the increase

in the proportion of the population with AST:ALT >2 over time may point to a growing burden

of alcohol-related liver disease, which is also associated with mortality. We previously

reported a signal suggesting a high prevalence of alcohol-related liver disease and liver

fibrosis in the GPC population (15). This is an area that could be strategically tackled

through education and public health interventions. However, it is unclear whether some of

the change in ratio is due to improvements in ALT over time, which may represent

regression to the mean, or other changes in population liver health over time.

Conversely, higher albumin was found to be protective against mortality. Albumin is a non-

specific marker which broadly provides a composite signal for nutrition, gut and renal health,

liver synthetic function, and the absence of uncontrolled chronic infection, malignant or

inflammatory disease. Due to these multiple influences that determine serum albumin

concentration, there is no single intervention that could be used to target hypoalbuminaemia,

but it is nevertheless important to consider albumin as a biomarker that could be used to

assess individual or population health.

Despite the significant advances in HIV diagnosis, treatment and care over time, HIV

infection in this population was still associated with increased mortality at the time of the

data collection. However, it should be noted that further improvements have continued over

time, and further investigation is required to determine whether this association has

lessened or diminished over time. HBV has an effect on mortality due mainly to cirrhosis and

hepatocellular carcinoma, and is a significant public health threat in many African countries.

A significant association between HBV and mortality emerged in our sensitivity analysis (HR

5.38), and requires further follow-up.

As expected, raised blood pressure is also associated with mortality, endorsing the need for

simple, affordable and effective interventions with monitoring, lifestyle changes, and

antihypertensive medication to save lives. In this analysis, although HbA1c is associated

with increased mortality, population values were low overall (S4). There was no statistically

significant relationship between BMI and mortality. However, serum albumin was inversely

associated with hazards of death, suggesting that hypoalbuminaemia is associated with an

increased mortality risk. Hypoalbuminaemia is a marker of inadequate nutrition (26), and

therefore we may be underpowered to detect an association of increasing BMI with mortality.

Implications of findings from sensitivity analyses

The associations of increasing age and HIV positivity with increasing hazards of death were

attenuated towards the null in the first sensitivity analysis, especially for the older age

categories. This likely reflects the influence of reverse causality bias as older participants

and those with HIV infection might have had clinically symptomatic and/or advanced disease

at recruitment. Only a minority of participants with longitudinal LFT measurement were

available for inclusion in sensitivity analyses, which affected our statistical power to detect

associations.

Strengths and limitations

This study reflects the health status of a broad population over time. LFTs and the metabolic

biomarkers we have reported have infrequently been routinely measured in whole-

population cohorts in WHO African countries due to resource and infrastructure constraints.

However, there are also sources of bias and data missingness, as people who are unwell

may be less willing or able to enrol in the cohort, and there is migration in and out of the

area. At follow-up, LFTs were only measured in a small subset of the cohort due to cost,

which affects the power of the study and may account for differences in results between the

main and sensitivity analyses. Thresholds for laboratory blood markers and biophysical

measurements have not been thoroughly validated in African populations.

Our analysis is based on data collected in 2010 and 2012, and there is a need for review of

new data in order to determine which of the effects we observe remain true a decade later.

We have described associations for which we can offer potential explanations, but factors

underlying these associations cannot be definitively determined through this study, and there

may be unmeasured confounding that influences our results. We have used all-cause

mortality as an endpoint, but further granularity could be added to analysis if causes of death

were available.

Conclusions

LFTs and metabolic markers are rarely measured in whole population cohorts in Africa, and

in this cohort we also had the opportunity to analyse longitudinal data for a subset of study

participants. Variables associated with excess mortality include AST/ALT ratio and GGT,

suggestive of an influence of alcohol. Higher HbA1c and systolic blood pressure, HIV and

HBV infection were also significant predictors of mortality at the time of the study. Male

vulnerability may need to be tackled by encouraging and supporting men to attend for

screening and health interventions. Further work is needed to determine the extent to which

these parameters have continued to influence mortality, in order to inform the delivery of

community health programmes.

DATA AVAILABILITY

A description of the study dataset, as well as access information/instruction for external individuals, is available on the London School of Hygiene and Tropical Medicine Data Compass: https://doi.org/10.17037/DATA.00004497.

FUNDING

CC received doctoral funding from the University of Oxford and GSK. PCM received Wellcome funding (ref 110110/Z/15/Z), and core funding from the Francis Crick Institute (ref CC2223) and University College London Biomedical Research Centre (NIHR BRC). This work received funding support from the University of Oxford John Fell Fund to the Uganda Liver Disease study ('ULIDS').

COMPETING INTERESTS

Under the supervision of PCM, CC received doctoral funding from GSK, outside the scope of this study.

ACKNOWLEDGEMENTS

We are grateful to the study teams and participants in the Uganda General Population Cohort.

REFERENCES

1.   Younossi ZM, Wong G, Anstee QM, Henry L. The Global Burden of Liver Disease.
Clin Gastroenterol Hepatol [Internet]. 2023 Jul 1 [cited 2023 Sep 24];21(8):1978–91.
Available from: https://pubmed.ncbi.nlm.nih.gov/37121527/
2.   Rinella ME, Lazarus J V, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A
multisociety Delphi consensus statement on new fatty liver disease nomenclature. J
Hepatol [Internet]. 2023 Dec 1 [cited 2024 Jun 13];79(6):1542–56. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/37364790
3.   Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-
associated steatotic liver disease: Update and impact of new nomenclature on the
American Association for the Study of Liver Diseases practice guidance on
nonalcoholic fatty liver disease. Hepatology [Internet]. 2024 May 1 [cited 2024 Jun
13];79(5):1212–9. Available from: https://pubmed.ncbi.nlm.nih.gov/38445559/
4.   Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma
glutamyltransferase and long-term survival: is it just the liver? Clin Chem [Internet].
2007 May [cited 2023 Mar 7];53(5):940–6. Available from:
https://pubmed.ncbi.nlm.nih.gov/17384006/
5.   Peltz-Sinvani N, Klempfner R, Ramaty E, Sela BA, Goldenberg I, Segal G. Low ALT
Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary
Heart Disease Patients. J Gen Intern Med [Internet]. 2016 Feb 1 [cited 2023 Mar
7];31(2):209–14. Available from: https://link.springer.com/article/10.1007/s11606-
015-3480-6
6.   Wang Y, Shi L, Wang Y, Yang H. An updated meta-analysis of AST and ALT levels
and the mortality of COVID-19 patients. Am J Emerg Med [Internet]. 2021 Feb 1
[cited 2023 Mar 7];40:208. Available from: /pmc/articles/PMC7251355/
7.   Liu H, Ding C, Hu L, Li M, Zhou W, Wang T, et al. The association between
AST/ALT ratio and all-cause and cardiovascular mortality in patients with
hypertension. Medicine [Internet]. 2021 Aug 8 [cited 2023 Mar 7];100(31):E26693.
Available from: /pmc/articles/PMC8341222/
8.   Tae HL, Kim WR, Benson JT, Therneau TM, Melton LJ. Serum aminotransferase
activity and mortality risk in a United States community. Hepatology [Internet]. 2008
Mar 1 [cited 2023 Mar 7];47(3):880–7. Available from:
https://onlinelibrary.wiley.com/doi/full/10.1002/hep.22090
9.   Hernaez R, Yeh HC, Lazo M, Chung HM, Hamilton JP, Koteish A, et al. Elevated
ALT and GGT predict all-cause mortality and hepatocellular carcinoma in Taiwanese
male: A case-cohort study. Hepatol Int [Internet]. 2013 Oct 17 [cited 2023 Mar
7];7(4):1040–9. Available from: https://link.springer.com/article/10.1007/s12072-013-
9476-6
10.   Wang T, Smith DA, Campbell C, Harris S, Salih H, Várnai KA, et al. Longitudinal
Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized
Patients With Corona Virus Disease 2019. Hepatol Commun [Internet]. 2021 Sep 1
[cited 2022 Mar 3];5(9):1586. Available from: /pmc/articles/PMC8239606/
11.   Mayén AL, Sabra M, Aglago EK, Perlemuter G, Voican C, Ramos I, et al. Hepatic
steatosis, metabolic dysfunction and risk of mortality: findings from a multinational
prospective cohort study. BMC Med [Internet]. 2024 Dec 1 [cited 2024 Jun

13];22(1):221. Available from:
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03366-3

12. Multimorbidity: Technical Series on Safer Primary Care. World Health Organisation [Internet]. 2016 [cited 2023 Mar 7];C BY-NC-SA 3.0 IGO. Available from: http://apps.who.int/bookorders.

13. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut [Internet]. 2017 [cited 2023 Mar 9];0:1–14. Available from: http://gut.bmj.com/

14. Berzigotti A, Governing Board representative E, Tsochatzis E, members P, Boursier J, Castera L, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. 2021 [cited 2023 Mar 7]; Available from: https://doi.org/10.1016/j.jhep.2021.05.025

15. O'Hara G, Mokaya J, Hau JP, Downs LO, McNaughton AL, Karabarinde A, et al. Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors. BMJ Open [Internet]. 2020 Mar 1 [cited 2023 Apr 11];10(3):e032890. Available from: https://bmjopen.bmj.com/content/10/3/e032890

16. Oni OO, Akinwusi PO, Odeyemi AO, Israel GM, Ala O, Akande JO, et al. Hypertension and its Clinical Correlates in a Rural Community in South Western Nigeria . West Afr J Med [Internet]. 2021 Mar [cited 2024 Jun 13];38(3):223–40. Available from: https://pubmed.ncbi.nlm.nih.gov/33765371/

17. Asiki G, Murphy G, Nakiyingi-Miiro J, Seeley J, Nsubuga RN, Karabarinde A, et al. The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. Int J Epidemiol [Internet]. 2013 Feb [cited 2023 Mar 13];42(1):129. Available from: /pmc/articles/PMC3600628/

18. World Health Organisation. WHO STEPS Surveillance Manual. 2017;

19. Murphy GAV, Asiki G, Ekoru K, Nsubuga RN, Nakiyingi-Miiro J, Young EH, et al. Sociodemographic distribution of non-communicable disease risk factors in rural Uganda: a cross-sectional study. Int J Epidemiol [Internet]. 2013 [cited 2024 Jun 14];42(6):1740–53. Available from: https://pubmed.ncbi.nlm.nih.gov/24191304/

20. Asiki G, Murphy GAV, Baisley K, Nsubuga RN, Karabarinde A, Newton R, et al. Prevalence of Dyslipidaemia and Associated Risk Factors in a Rural Population in South-Western Uganda: A Community Based Survey. PLoS One [Internet]. 2015 May 14 [cited 2024 Jun 17];10(5). Available from: /pmc/articles/PMC4431752/

21. Kalyesubula R, Sekitoleko I, Tomlin K, Hansen CH, Ssebunya B, Makanga R, et al. Association of impaired kidney function with mortality in rural Uganda: results of a general population cohort study. BMJ Open [Internet]. 2022 Apr 1 [cited 2023 Mar 13];12(4):e051267. Available from: https://bmjopen.bmj.com/content/12/4/e051267

22. Salaspuro M. Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme [Internet]. 1987 [cited 2023 Apr 11];37(1–2):87–107. Available from: https://pubmed.ncbi.nlm.nih.gov/2436906/

23. Botros M, Sikaris KA. The De Ritis Ratio: The Test of Time. Clin Biochem Rev [Internet]. 2013 [cited 2023 Apr 11];34(3):117. Available from: /pmc/articles/PMC3866949/

24. Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci [Internet]. 1979 [cited 2023 Apr 11];24(11):835–8. Available from: https://pubmed.ncbi.nlm.nih.gov/520102/

25. Correia JP, Alves PS, Camilo EA. SGOT-SGPT ratios. Dig Dis Sci [Internet]. 1981 Mar [cited 2023 Apr 11];26(3):284. Available from: https://pubmed.ncbi.nlm.nih.gov/7238254/

481   26.   Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and Clinical
482   Significance. Journal of Parenteral and Enteral Nutrition [Internet]. 2019 Feb 1 [cited
483   2024 Jun 13];43(2):181–93. Available from:
484   https://onlinelibrary.wiley.com/doi/full/10.1002/jpen.1451

 TABLES AND FIGURES

488
489 **Table 1. Baseline characteristics for a subset of individuals included in the Uganda MRC**
490 **General Population for whom liver function test measurement was performed.** Characteristics
491 are reported overall and by survival status after a mean follow up of 6.4 years from 2010 to 2023.
492 Liver function test resurvey was conducted in a subset of individuals in 2012/2013.
493

Characteristic	Total	Died	Survived
Number of participants	7896	629 (7.97)	7267 (92.03)
Sex			
Male, n (%)	3455 (43.8)	340 (54.1)	3115 (42.9)
Age group, n (%)			
Age (years), mean (SD)	34.01 (18.36)	59.4 (19.5)	31.8 (16.5)
<18 years	1982 (25.1)	26 (4.1)	1956 (26.9)
18-24 years	1198 (15.2)	15 (2.4)	1183 (16.3)
25-34 years	1379 (17.5)	48 (7.6)	1331 (18.3)
35-44 years	1163 (14.7)	53 (8.4)	1110 (15.3)
45-54 years	936 (11.9)	75 (11.9)	861 (11.8)
55-64 years	578 (7.3)	107 (17.0)	471 (6.5)
65-74 years	414 (5.2)	152 (24.2)	262 (3.6)
≥75 years	246 (3.1)	153 (24.3)	93 (1.3)
Liver function tests			
Abnormal ALT, NICE cut-off, n (%)	2020 (25.6)	140 (22.3)	1880 (25.9)
AST:ALT ratio, median (IQR)	1.43 (1.19, 1.71)	1.64 (1.34, 1.96)	1.42 (1.18, 1.68)
AST:ALT ratio > 2, n (%)	857 (10.9)	147 (23.4)	710 (9.8)
ALP, median (IQR)	92.52 (71.23, 144.40)	90.79 (74.85, 116.05)	92.67 (70.82, 150.53)
Abnormal AST, NHS cut-off, n (%)	635 (8.0)	92 (14.6)	543 (7.5)
GGT, median (IQR)	1.88 (1.35, 2.79)	2.58 (1.69, 4.68)	1.84 (1.33, 2.67)
Bilirubin, median (IQR)	0.76 (0.52, 1.20)	0.73 (0.49, 1.10)	0.77 (0.52, 1.21)
Albumin, median (IQR)	41.70 (39.25, 43.85)	38.89 (35.00, 41.69)	41.89 (39.57, 44.00)
Lipid profile			
Cholesterol, median (IQR)	3.41 (2.84, 4.07)	3.63 (2.94, 4.36)	3.39 (2.84, 4.05)
HDL, median (IQR)	0.96 (0.74, 1.20)	1.02 (0.78, 1.32)	0.95 (0.73, 1.19)
LDL, median (IQR)	1.93 (1.50, 2.43)	2.00 (1.44, 2.58)	1.92 (1.50, 2.43)
Triglycerides, median (IQR)	1.05 (0.78, 1.43)	1.14 (0.85, 1.55)	1.04 (0.78, 1.41)
HbA1c, median (IQR)	3.33 (2.95, 3.70)	3.45 (3.04, 3.85)	3.32 (2.94, 3.69)
BMI			
BMI (kg/m^2), mean (SD)	20.66 (18.71, 22.90)	19.74 (17.78, 22.22)	20.70 (18.79, 22.95)
<18.5 kg/m^2, n (%)	1678 (22.8)	180 (31.9)	1498 (22.0)
18.5 to 24.9 kg/m^2, n (%)	4769 (64.8)	324 (57.3)	4445 (65.4)

25 to 29.9 kg/m^2, n (%)	718 (9.8)	42 (7.4)	676 (9.9)
30 to 34.9 kg/m^2, n (%)	147 (2.0)	13 (2.3)	134 (2.0)
>=35 kg/m^2, n (%)	50 (0.7)	6 (1.1)	44 (0.6)
BP			
Average systolic BP, median (IQR)	73 (68, 80)	131 (118, 152)	119 (111, 129)
Average diastolic BP, median (IQR)	120 (112, 130)	78 (71, 87)	73 (67, 80)
HIV status			
Negative, n (%)	7314 (92.6)	564 (89.7)	6750 (92.9)
Positive, n (%)	582 (7.4)	65 (10.3)	517 (7.1)
HBV status			
Negative, n (%)	7680 (97.3)	611 (97.1)	7069 (97.3)
Positive, n (%)	216 (2.7)	18 (2.9)	198 (2.7)
Longitudinal follow-up available			
Resurveyed, n (%)	900 (11.4%)	45 (7.2%)	853 (11.7%)

494
495 ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aminotransferase; IQR, interquartile
496 range; GGT, gamma glutamyl-transferase; HDL, high density lipoprotein; LDL, low density lipoprotein;
497 HbA1c, hemoglobin A1c; BMI, body mass index; BP, blood pressure; HIV, human immunodeficiency
498 virus; HBV hepatitis B virus.
499

500 **Table 2**. Liver functions tests in the complete Uganda General Population Cohort at baseline (n =
501 7896) and in participants who were (n = 898) and were not (n = 6998) resurveyed in round 24.
502

Characteristic	Measurement at baseline	Measurement at follow-up
Abnormal ALT, NHS cut-off, n (%) Participants under longitudinal follow-up Participants not under longitudinal follow-up	258 (28.7) 1762 (25.2)	122 (13.6)*** N/A
ALT, median (IQR) Participants under longitudinal follow-up Participants not under longitudinal follow-up	18.23 [14.19,23.55] 17.72 [13.96, 22.78]	11.30 [6.70, 17.28] N/A
AST, median (IQR) Participants under longitudinal follow-up Participants not under longitudinal follow-up	25.64 [21.76, 31.22] 25.08 [21.13, 30.27]	19.50 [13.70, 25.90] N/A
AST:ALT ratio, median (IQR) Participants under longitudinal follow-up Participants not under longitudinal follow-up	1.44 [1.20, 1.71] 1.42 [1.17, 1.72]	1.73 [1.34, 2.30] N/A
AST:ALT ratio > 2, n (%) Participants under longitudinal follow-up Participants not under longitudinal follow-up	101 (11.2) 756 (10.8)	323 (36.0) *** N/A
GGT, median (IQR) Participants under longitudinal follow-up Participants not under longitudinal follow-up	19.22 [14.05, 28.20] 18.72 [13.46, 27.80]	15.00 [10.00, 23.00] N/A

ALT, alanine aminotransferase; AST, aminotransferase; IQR, interquartile range; SD, standard
deviation; GGT, gamma glutamyltransferase; N/A, not applicable.
* $P < 0.05$; P-value for difference in proportion between those measured at baseline and measured at
follow-up.
** $P < 0.01$; P-value for difference in proportion between those measured at baseline and measured
at follow-up.
*** $P < 0.001$; P-value for difference in proportion between those measured at baseline and measured
at follow-up.

Figure 1. Timeline of the Uganda MRC General Population cohort, showing timepoints

of data collection for this study in survey rounds 22 and 24. The cohort was established

in 1989, with the study population recruited via annual household census rounds. Follow-up

for detection of relevant endpoints (deaths in this study) is available up to 2022.

520 **Figure 2: Forest plot for Cox proportional hazards model to identify risk factors for all-**

521 **cause mortality in the Uganda General Population Cohort study (n = 7341, deaths =**

522 **563) followed up for a mean 6.4 (SD 3.2) years.** This plot includes the estimates for the

523 most parsimonious multivariable model (parameters excluded if univariable associations not

524 significant).

HR, hazards ratio; CI, confidence interval; GGT, gamma glutamyltransferase; HbA1c, hemoglobin

A1c; BP, blood pressure; HIV, human immunodeficiency virus; HBV hepatitis B virus; LDL, low

density lipoprotein; ALT, alanine aminotransferase; AST, aminotransferase; BMI, body mass index;.

* Hazards ratio per 10 unit increase in serum GGT.

† Hazards ratio per 10 unit increase in systolic blood pressure.

* $P < 0.05$
** $P < 0.01$
*** $P < 0.001$

SUPPLEMENTARY MATERIAL

S1. Suppl methods

Blood pressure was measured on the right arm using appropriate cuff sizes (regular arm cuff size if arm circumference was 24-32cm, large arm cuff if arm circumference was 33-41cm, thigh cuff if over 41cm and if under 24cm paediatric cuff size was used) in a sitting position, three times within resting intervals of 5 minutes, using a digital sphygmomanometer (the Omron M4-I). The mean of the second and third reading was taken for analysis. Body weight was measured using the Seca 761 mechanical scales and body height was measured using a portable Leicester stadiometer to the nearest 1 kg and 0.1 cm respectively, with participants wearing light clothing and no shoes.

HIV testing was based on initial screening with a rapid test. If the test result was negative, the participant was considered to be HIV negative. If the test result was positive, the sample was retested with the rapid test HIV-1 or HIV-2 Stat-Pak. If both tests resulted in a positive result, the participant was diagnosed as HIV positive. If the tests gave discordant results, the sample was further evaluated with the rapid test Uni-Gold Recombinant HIV-1/2. For those samples assessed by all three tests, two positive test results were interpreted as positive, and two negative results were considered negative. HBV surface antigen (HBsAg) testing was conducted using Cobas HBsAg II (2011–08 V.10), and those who tested positive were invited for further serologic testing. HCV was tested using a combination of immunoassays followed by PCR, as previously described (15).

S2. STROBE Statement.

Section in Paper	Item No.	Recommendation	Notes
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Cohort study indicated in title
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract presented to include background, methods, key findings and rationale.
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction explains case of need.
Objectives	3	State specific objectives, including any prespecified hypotheses	Specific aims stated at the end of introduction section
Methods			
Study design	4	Present key elements of study design early in the paper	Study design presented in methods with figure 1 to show timeline.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Details included in methods.
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Details included in methods and through reference to other papers.
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Relevant markers described in methods section. Ascertainment of primary outcome (mortality) described in methods.
Data sources / measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Measurements, variables and reference ranges (where relevant) stated in methods
Bias	9	Describe any efforts to address potential sources of bias	Bias and missingness addressed in the discussion section.
Study size	10	Explain how the study size was arrived at	N/A – we used full data from a community population cohort (described in methods)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Handling of quantitative data is described in methods.
Statistical methods	12	(*a*) Describe all statistical methods, including those used	Statistical approaches presented in methods.

			to control for confounding
		(*b*) Describe any methods used to examine subgroups and interactions	Statistical approaches presented in methods. No subgroups or interactions were examined, but sensitivity analysis was undertaken to test robustness of the main analysis to reverse causality bias.
		(*c*) Explain how missing data were addressed	Statistical approaches presented in methods. Sensitivity analysis undertaken in patients who were resurveyed after baseline measurement.
		(*d*) If applicable, explain how loss to follow-up was addressed	Statistical approaches presented in methods. Verbal autopsies are undertaken to ensure completeness of death records.
		(*e*) Describe any sensitivity analyses	Sensitivity analyses described.
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Numbers are described and presented in results, tables and figure 1.
		(b) Give reasons for non-participation at each stage	Description of loss to follow-up is presented
		(c) Consider use of a flow diagram	Flow diagram (timeline) is included.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Descriptive data are presented in Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Number of participants under follow up presented in Table 2
		(c) Summarise follow-up time (eg, average and total amount)	Follow-up time presented in results and in Figure 1
Outcome data	15*	Report numbers of outcome events or summary measures over time	Outcome events (mortality) presented in results section.
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Presented in tables.
		(*b*) Report category boundaries when continuous variables were categorized	Presented in methods
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a	N/A

		meaningful time period	
Other analyses	17	Report other analyses done— eg analyses of subgroups and interactions, and sensitivity analyses	Sensitivity analyses conducted and presented in supplementary table.
Discussion			
Key results	18	Summarise key results with reference to study objectives	Presented in results and discussion.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Presented in discussion.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Presented in discussion.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Presented in discussion.
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Funding information is presented at the end of the article.

568
569
570

571
572 **S3. Cox proportional hazards model for mortality based on univariable associations, complete case main**
573 **model (n = 7341, deaths = 563) and sensitivity analyses.** Sensitivity analysis I: excluding deaths occurring in
574 the first 3 years of follow-up (n = 5641, deaths = 427). Sensitivity analysis II: restricted to participants with
575 longitudinal LFT measurement (n = 871, deaths = 44).
576

Characteristic	Univariable HR (95% CI)	Multivariable HR (95% CI)	Multivariable HR sensitivity analysis I (95% CI)	Multivariable HR sensitivity analysis II (95% CI)
Age group, n (%)				
<18 years	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
18-24 years	0.89 (0.47 to 1.69)	0.86 (0.43 to 1.72)	0.6 (0.26 to 1.36)	2.17 (0.13 to 35.18)
25-34 years	1.72 (1.07 to 2.78)*	1.81 (1.09 to 3.03)*	1.2 (0.68 to 2.14)	5 (0.62 to 40.37)
35-44 years	1.96 (1.23 to 3.14)**	1.57 (0.94 to 2.62)	1.18 (0.67 to 2.06)	2.17 (0.24 to 19.84)
45-54 years	3.28 (2.1 to 5.14)***	2.32 (1.43 to 3.78)***	1.85 (1.09 to 3.14)*	7.56 (0.89 to 64.15)
55-64 years	7.1 (4.62 to 10.93)***	5.02 (3.15 to 8.01)***	3.9 (2.35 to 6.48)***	8.73 (1.05 to 72.87)
65-74 years	14.87 (9.79 to 22.59)***	8.21 (5.13 to 13.14)***	6.16 (3.68 to 10.31)***	7.03 (0.82 to 60.01)
≥75 years	25.04 (16.4 to 38.23)***	13.09 (8.12 to 21.1)***	9.16 (5.41 to 15.5)***	31.77 (3.83 to 263.64)***
Sex, n (%)				
Female	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Male	1.42 (1.22 to 1.67)***	1.56 (1.3 to 1.86)***	1.49 (1.22 to 1.83)***	2.12 (1.01 to 4.45)*
LFTs, cardiovascular and metabolic markers				
GGT*	1.01 (1.01 to 1.02)***	1.01 (1.01 to 1.01)***	1.01 (1.00 to 1.01)*	1.02 (0.95 to 1.08)
AST:ALT ratio	1.32 (1.26 to 1.39)***	1.17 (1.08 to 1.26)***	1.23 (1.11 to 1.36)***	0.87 (0.58 to 1.3)
Albumin	0.86 (0.85 to 0.87)***	0.9 (0.88 to 0.92)***	0.92 (0.9 to 0.94)***	0.91 (0.86 to 0.97)***
HbA1c	1.25 (1.16 to 1.35)***	1.25 (1.13 to 1.38)***	1.23 (1.07 to 1.41)***	0.89 (0.57 to 1.4)
Average systolic BP †	1.25 (1.21 to 1.29)***	1.07 (1.03 to 1.11)***	1.08 (1.03 to 1.13)***	1.21 (1.07 to 1.38)***
LDL quintiles				
First	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Second	0.59 (0.46 to 0.77)***	0.67 (0.5 to 0.89)*	0.69 (0.49 to 0.96)*	0.68 (0.27 to 1.71)
Third	0.74 (0.58 to 0.95)*	0.86 (0.65 to 1.13)	0.93 (0.67 to 1.28)	0.65 (0.25 to 1.71)
Fourth	0.76 (0.6 to 0.97)*	0.89 (0.67 to 1.18)	0.93 (0.67 to 1.28)	0.77 (0.32 to 1.84)
Fifth	0.81 (0.64 to 1.01)	0.76 (0.57 to 1.01)	0.72 (0.52 to 1)	0.42 (0.13 to 1.36)
HIV status				
HIV positivity	1.41 (1.09 to 1.82)**	1.67 (1.25 to 2.22)***	1.31 (0.91 to 1.88)	1.89 (0.65 to 5.44)

HBV positivity	0.95 (0.59 to 1.52)	0.86 (0.51 to 1.45)	0.84 (0.47 to 1.51)	5.38 (2.01 to 14.42)***
BMI, n (%)				
Underweight (<18.5 kg/m^2)	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Normal weight (18.5-24.9 kg/m^2)	0.63 (0.52 to 0.75)***	0.82 (0.67 to 1)	0.94 (0.75 to 1.19)	0.57 (0.3 to 1.09)
Overweight (25.0-29.9 kg/m^2)	0.56 (0.4 to 0.79)***	0.89 (0.62 to 1.29)	0.96 (0.63 to 1.47)	0.25 (0.03 to 2.01)
Obesity class (30.0 to 34.9 kg/m^2)	0.7 (0.4 to 1.23)	0.9 (0.5 to 1.63)	0.92 (0.47 to 1.82)	1.27 (0.18 to 8.93)
Obesity classes II and III (≥35 kg/m^2)	1.01 (0.44 to 2.27)	1 (0.44 to 2.28)	1.42 (0.62 to 3.3)	2.45 (0.21 to 29.07)

577
HR, hazards ratio; CI, confidence interval; GGT, gamma glutamyltransferase; HbA1c, hemoglobin
A1c; BP, blood pressure; HIV, human immunodeficiency virus; HBV hepatitis B virus; LDL, low
density lipoprotein; ALT, alanine aminotransferase; AST, aminotransferase; BMI, body mass index;.
* Hazards ratio per 10 unit increase in serum GGT.
† Hazards ratio per 10 unit increase in systolic blood pressure.
* *P* < 0.05
** *P* < 0.01
*** *P* < 0.001

587 **S4. Relationship between body mass index and HbA1c.** As anticipated, as BMI increases, so does
588 HbA1c, but HbA1c values in this population are low (confidence intervals do not span the clinically
589 important thresholds of 5.7% which represents a cut-off for pre-diabetes and 6.5% which indicates
590 diabetes).
591